Acquired resistance remains a central challenge for KRAS-directed drug discovery. ICE Bioscience provides drug-resistant cancer cell models spanning KRAS G12C, KRAS G12D, and pan-RAS inhibitor programs across pancreatic, colorectal, and lung cancer backgrounds.
Generated through in vitro drug-induced resistance selection, these models support resistance-focused pharmacology studies, comparative response profiling, and mechanism-of-action investigations using genomic and transcriptomic analysis.
Select resistant models by cancer indication, inhibitor, and KRAS target class.
Compare parental and resistant models to characterize changes in compound response.
Combine whole-exome sequencing and RNA-seq to investigate candidate resistance mechanisms.
The current portfolio includes 13 resistant models generated by in vitro drug-induced resistance selection. Additional models are continually being developed and added to the portfolio.
Whole-exome sequencing (WES) and RNA sequencing (RNA-seq) can be applied to parental-versus-resistant model pairs to identify candidate genomic alterations, pathway rewiring, and transcriptional programs associated with drug resistance.
Discuss your KRAS resistance model requirements with our scientific team to identify an appropriate cancer background, inhibitor-resistance context, and molecular follow-up strategy.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
Get a quote
Go top
